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Placental site trophoblastic tumor is rare. They represent a rare form of gestational tro-
phoblastic disease. They occur mainly in women who have a history of miscarriage,
termination of pregnancy, or even a normal or pathological ongoing pregnancy. The clinical
course is unpredictable. This malignancy has different characteristics from other gesta-
tional trophoblastic tumors. Following a clinical case that we encountered and treated,
we conducted a literary research and review, focusing primarily on prognostic factors and
treatment.
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INTRODUCTION
Placental site trophoblastic tumor (PSTT) is a rare tumor, repre-
senting from 0.23 (1) to 3% (2) of gestational trophoblastic dis-
eases (GTD). “Up to date” state that 300 cases have been reported
in the literature (3). It mainly affects women of childbearing age,
after pregnancy.
Placental site trophoblastic tumor differs from other GTD by a
slow growth and a relative resistance to chemotherapy.
CLINICAL CASE
A 30-year-old patient, gravida 1 and para 0, gave birth natu-
rally and without complications to a boy weighing 3290 g in May
2011 after a previous normal delivery in 2008 of a girl weigh-
ing 2970 g. Five months after her second delivery, the patient
presented with bleeding (metrorrhagia). The pelvic echography
showed no distinctive characteristics. A slightly high level of beta-
HCG was observed (see Table 1). The presumed diagnosis was
a trophoblastic retention. An operative hysteroscopy allowed the
removal of 5 cc material. Its histology demonstrated the presence
of several trophoblastic viable cells or nearly pyknotic trophoblas-
tic looking cells without signs of malignancy. A weekly follow-up
of beta-HCG was instituted, and the patient was treated with an
oestroprogestative contraception.
Given the stagnation of beta-HCG during 2 weeks, a further
operative hysteroscopy with 3 cc of product removal was carried
out. After proofreading the blades and further immunohistochem-
ical study, the diagnosis of PSTT was elected.
The extensive workup included a thoracic-abdominal-pelvic
CT, which showed a large sized uterus displaying a heteroge-
neous rising with moderate bilateral ecstasy of the uterine veins. A
cerebral MRI and a PET-CT did not detect the presence of metas-
tasis. After discussion with the couple, a total hysterectomy with
preservation of ovaries was decided. Intraoperative exploration is
unremarkable except for bilateral uterine venous ecstasy.
Final histology confirmed a PSTT with a diameter of 23 mm,
with infiltration of> 50% of the myometrium. The immunohisto-
chemistry showed strongly positive tumorous staining for inhibin,
partially positive staining for beta-HCG and for HPL (placental
lactogenic hormone), and negative staining for p63. In addition,
the Mib-1(Ki67) has reached 10–15% by locations (see Figure 1).
DISCUSSION
Placental site trophoblastic tumor is a subtype of GTH. These
include partial and complete hydatidiform moles, invasive moles,
choriocarcinoma, PSTT, and epithelioid trophoblastic tumors
(TTE). The last three potential entities are grouped under the
term gestational trophoblastic neoplasia, given their potential
malignancy (4).
The cell proliferation in GTD comes from the placental
trophoblast. It consists of syncytiotrophoblast, cytotrophoblast,
and intermediate trophoblast. The syncytiotrophoblastic cells are
polynuclear cells that form the external layer, mainly produce
human chorionic gonadtropin (HCG) and invade the endome-
trial stroma. The cytotrophoblasts form the basal layer, whose
cells can differentiate in syncytiotrophoblastic cells or intermedi-
ate trophoblastic cells. The intermediate trophoblastic cells leave
the placenta to restructure the spiral arterioles in order to decrease
the blood flow resistance toward the placenta (4, 5). PSTTs come
from these spiral arterioles (6).
Histologically, PSTTs consist in a proliferation of intermediate
trophoblastic cells without chorionic villi infiltrating muscle fibers
(7). They are characterized with a vascular invasion, a necrosis, and
hemorrhage at a lesser extent than choriocarcinoma, and a bigger
tendency to disseminate through the lymphatic track (3, 4).
The immunohistochemical analysis shows a strongly positive
staining for HPL; a generally weak and focal positive staining
for HCG (3, 7, 8); a diffuse positive staining for cytokeratin (7),
a strong positive staining for epidermal growth factor receptor
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(EGFR) and vascular endothelial growth factor (VEGF); and a
negative staining for human epidermal receptor2/neu (HER2/neu)
and cluster of differentiation117 (CD117) (3). The pregnancy-
associated major basic protein (pMBP), a marker of the interme-
diate trophoblast, turns out useful in differentiating PSTT from
other forms of TTE (9).
As for the tumor’s pathogenesis, this remains to be clarified. Hui
and colleagues found an absence of Y-chromosome in 20 cases of
PSTT with a haploid pair of X chromosomes. They suggest the
paternal X chromosome has a functional role in this tumor, with
a more important expression of the genes responsible for growth
in the paternal genome (6). Other authors report a predominance
of female fetuses (11 female fetuses for 2 male ones) among the
pregnancies carried to term that were the source of a PSTT (1).
The first case of PSTT was described in 1976 by Kurman and
colleagues on a series of 12 cases, referred to as “trophoblastic
pseudo tumor,” for a supposed benign pathology. Since then, just
fewer than 300 cases have been described in the literature, with an







assured potential for malignancy. The terminology was therefore
adapted to the current PSTT denomination in 1981, through the
works of Scully (10).
Placental site trophoblastic tumor can arise during or after a
normal pregnancy, a miscarriage, an abortion, or a molar preg-
nancy, and can occur during post-menopause, years after the
last pregnancy ((1, 3, 7), and (11)). A case describes multi-
ple metastases in a 4-month-old male infant who consequently
died (12).
The primary tumor site is nearly always located in the corpus
or the fundus of the uterus, but two cases of cervical location have
been described (13).
The patients’ age is between 20 (14) and 63 years old (3),
32 years old on average (7). The gap since the last pregnancy is
on average 34 months (median of 18 months) after the last-known
pregnancy.
In the literature, the mean gestity is 2, 2 (14).
Symptomatology is variable. It can be amenorrhea (1, 14),
bleeding ((14, 15), (1)), uterine rupture (1), abdominal pain (1),
post-menopausal bleeding (1), virilization (16), or symptoms due
to metastases (1,17). Cases of nephritic syndrome on membranous
glomerulonephritis have been described, regressing after treating
the tumor (18, 19). Some cases were asymptomatic and only the
persistent increase in beta-HCG levels led to the diagnosis (14).
The stage of the illness is determined by the gestational TTE
FIGO stage (see Tables 2 and 3).
The majority of diagnosed cases are at stage I in the classifica-
tion of GTD according to FIGO (limited to the uterus), 14 (7) to
31% (20) of the cases initially with metastases manifested.
FIGURE 1 | Histologic sections. (A) Myometrium infiltration by tumor cells, (B) vascular invasion, (C) inhibin marking, and (D) HPL marking.
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The metastases sites are (from most frequent to rare): lungs
(7), liver (1, 7), vagina (1, 7), gastrointestinal tract (7), brain (1, 7),
lymph nodes (3, 7), bladder (7), ovary (7, 21), omentum (7), tho-
racic diaphragm (7), pancreas (1, 7), spleen (7), kidney (1), bone
marrow (7), and scalp (22).
The tendency to metastasize through lymphatic ways seems
significant, as 5.9% of cases have lymphatic metastases during
diagnosis or at the time of recurrence. The lymphatic metas-
tases sites are (from most frequent to least frequent): para-aortic
(50%), pelvic (35.7%), non-specified retroperitoneal (14.3%),
inguinal (7.1%), renal hilum (7.1%), mesenteric (7.1%), medi-
astinal (7.1%), hilar (7.1%), and supraclavicular (7.1%) (3). Lan
and colleagues suggest to conduct a retroperitoneal lymphadenec-
tomy on stage 1 patients who have risk factors such as myometrium
invasion> 50% as well as all stages II patients. For other stages,
the lymphadenectomy depends on the location and on the resect
ability of the other metastases (3).
When looking at the biology, the beta-HCG levels are moder-
ately high, unlike the levels found in the hydatiform moles. In 79%
of cases, the level is lower than 1000 IU/l and in 58% of cases, it is
lower than 500 IU/l (23).
Through a routine trans-vaginal ultrasound, one can see the
tumor or not, it can have a solid or cystic aspect (24, 25). The
invasion and destruction of the myometrium vascularization can
cause the formation of blood deficiencies and of artery-venous
shunt with hemodynamic modifications (26). Some authors have
noticed that the tumor vessels have low resistance with high
diastolic velocity (25, 26). Bettencourt and colleagues suggest a
Doppler monitoring to monitor the response to chemotherapy as
well as a monitoring of the beta-HCG level (26).
On the MRI, the specifications of PSTT are non-specific
(27). In the case of tumors that are invisible on the ultra-
sound, MRI is particularly interesting to locate the tumor and
Table 2 | Anatomical classification FIGO 2000.
I Limited to the uterus
II Extended outside the uterus but limited to genital structure
III Extended to lungs with or without known genital tract reached
IV Any other site of metastatis
determine the loco-regional extension, thus allowing guidance of
treatment (27).
Placental site trophoblastic tumor behavior is characterized by a
slower growth, when compared to other TTE, as well as a tendency
to diffuse through lymphatic ways. Therefore, they are relatively
resistant to chemotherapies (3).
The preferred treatment for PSTT is essentially surgical and is
based on hysterectomy (1, 14, 15, 28) with lymphatic sampling (8,
29). Conducting a lymphadenectomy at stage 1 seems particularly
appropriate in case of risk factors such as a myometrium invasion
superior to 50% (3). Please note that the lymphatic metastases
are not listed in the FIGO classification system. The hysterectomy
can be inter-adnexal on pre-menopausal patients without a high
ovarian carcinoma family risk (8, 24).
Several cases of located tumor resection, with the aim to pre-
serve fertility, have been described (30–32). In many cases, an
additional hysterectomy was consequently required (inadequate
or invaded resection margins, beta-HCG post-operative increase
with diffuse myometrium infiltration) (31). In the series described
by Saso and colleagues, a case of partial resection through a mod-
ified Strasmann procedure allowed to preserve the fertility of
a patient. A patient described by Tsuji and colleagues was also
treated in such a way as to conserve the uterus with neo-adjuvant
chemotherapy by EMA/CO and then tumor resection by laparo-
tomy (30). Shen and colleagues describe six patients successfully
treated by a combination of surgery and chemotherapy with uter-
ine conservation. A pregnancy carried to term was reported among
one of these patients (32).
In any case, the success level of a conservative treatment is low
and this option should be proposed only after an extensive discus-
sion and detailed patient information. It should be reserved for
young patients not finding any poor prognosis factors and whose
tumor is focal (32).
As far as adjuvant therapies are concerned, Schmid and col-
leagues have not demonstrated the benefit of chemotherapy for
stage I patients (8). On the other hand, a combined surgery and
chemotherapy treatment is recommended from stage II onward
(8, 28). For stage I cases, with poor prognosis factors, such
as a long-time interval since the last pregnancy (28), a high
mitotic index [Hoekstra et al. – (28)], a vascular invasion, a deep
myometrium invasion, an invasion of the serous membrane, or
Table 3 | Stage of the disease at diagnosis.
Studies No. of cases Stage I (%) Stage II (%) Stage III (%) Stage IV (%) Non-set (%)
Chen et al. (15) 17 88.2 0 11.8 0
Feltmate et al. (14) 13 69.2 30.8 0 0
Baergen et al. (7) 55 84 2 5 9
Lan et al. (3) 5 40 40 20 0
Hassadia et al. (1) 17 47.1 5.9 29.4 17.6
Chang et al. (20) 88 65.9 4.5 11.4 12.5 5.7
Schmid et al. (8) 62 55 8 26 11
Hoekstra et al. (28) 7 57 0 0 43
Papadopoulos et al. (23) 34 44 24 29 3
Shen et al. (32) 6 100
Zhao et al. (37) 11
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for cases with persistence of high post-operative beta-HCG levels,
chemotherapy could also be recommended (8, 14, 29). In a series
of cases, Feltmate and colleagues found that the prognosis was
improved when starting chemotherapy during the week following
the operation (14).
In comparison with other gestational TTE, the response to
chemotherapy is lower in PSTT, with 61% resistance or incomplete
response (8).
Comparative data from different chemotherapy schemes are
missing. The ones that are generally administrated are: EMA/CO
(7) or EMA/EP (8, 14, 24, 29), without a difference being revealed
between the EMA/EP, EMA/CO, or EMA schemes, or between the
diets with or without platines (8) (see Table 4).
For second-line therapies, there is no consensus, the EMA/EP
scheme is proposed in the case of recurrences after EMA/CO (7),
or BEP (7, 33) or VIP (7) schemes.
The resection of residual lumps after chemotherapy is recom-
mended, given the lower sensitivity of tumor cells after chemother-
apy, which is confirmed by presence of viable tumor cells in the
specimen resected after primary chemotherapy (8, 34, 35).
Table 4 | Protocol of chemotherapy.
EMA/EP EMA 0.5 mg dactinomycin iv J 1 et 2
100 mg/m2 etoposide iv J 1 et 2
300 mg/m2 methotrexate iv J1
15 mg folic ac po 2x/j J 2 et 3
EP 150 mg/m2 etoposide iv J8
75 mg/m2 cisplatin iv J8
MAE 300 mg/m2 methotrexate iv J1
15 mg folic ac po 4x/j J 2 et 3
0.5mg dactinomycin iv J 8 à 10
100 mg/m2 etoposide iv J 8 à 10
BEP bleomycin 30 mg iv J1, 8, 15
etoposide 100mg/m2 J1 à 5
cisplatin 20 mg/m2 J1 à 5
VIP etoposide 75 mg/m2 J1 à 5
ifosfamide 1.2 g/m2 J1 à 5
cisplatin 20 mg/m2 J1 à 5
According to Feltmate and colleagues, radiotherapy can be
effective for loco-regional control and remains rarely recom-
mended (14).
The factors that are most strongly correlated with poor progno-
sis, which were found in almost all series, are a high stage according
to FIGO (1, 7, 8, 20, 28) (Table 5). The value of the FIGO risk scores
is controversial (Table 6). According to Hassadia and colleagues,
it should not be used (1, 36), but Schmid and colleagues’s study
shows a correlation with survival (8).
Other poor prognosis factors are an interval of more than
24 months since the last pregnancy (7, 8, 23, 28), a level of mitosis
higher than 6 in 10 bigs fields (7, 8, 14), an age older than 34 years
(1, 7, 8), a term birth for the last pregnancy (7), a myometrium
invasion of more than 50% (7), an extensive coagulation necrosis
(7), and cells with clear cytoplasm (7).
A beta-HCG level higher than 1000 IU/l (7, 8) is also a poor
prognosis factor. On the other hand, this rate is not correlated to
the tumor mass (1).
CONCLUSION
Placental site trophoblastic tumors are exceptional tumors,
encountering difficult clinical and histological diagnosis.
Immunohistochemistry plays an important role, and our case
underlines the importance of reading through the blades several
times.
Clinically speaking, their emergence is seldom or not at
all predictable because their generally appear after a normal
pregnancy.
The usual symptoms are non-specific, such as metrorrhagia or
amenorrhea, sometimes years after the last pregnancy. From a bio-
logical point of view, the dosage and follow up of beta-HCG levels
are interesting for the diagnosis, but one must keep in mind that
the levels are not as high as in other GTH.
The only FIGO classification criticism for GTHs is that the
lymphatic spread is not taken into account.
In the case of PSTT, the most commonly recognized risk factors
are: stage, mitosis rate, elapsed time since last pregnancy at the time
of diagnosis, age of the patient, and the degree of myometrium
invasion.
With regard to treatment, the leading role of surgery must be
underlined, generally through hysterectomy. The possibility of a
Table 5 | Prognostic scores (FIGO 2000).
0 1 2 4
Age <40 ≥40 – –
Previous pregnancy Mole Abortion Pregnancy on term –
Delay between the end of pregnancy and the
beginning of chemotherapy
<4 mois 4–7 7–13 >13
Plasmatic HCG before the treatment (IU/l) <103 103–104 104–105 >105
Larger tumor – 3–5 >5 –
Metastatic sites Lang (standard X Ray) Kidney, spleen Bowel, ileon Brain, liver
Number of metastatis 0 1-4 5-8 >8
Failure of prior chemo therapy – – Mono-chemotherapy Poly-chemotherapy
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Table 6 | Analysis of literature.
Chen et al. (15) 17 Cases Hysterectomy with or without EMA-CO chemotherapy is a beneficial treatment modality.
Feltmate et al. (14) 13 Cases High mitotic index appears to be an adverse prognostic indicator for recurrence. Hysterectomy remains the
mainstay of treatment. Chemotherapy is indicated for patients with metastases and may be indicated when the
mitotic index is>5 Mitoses/10 HPF. Radiation treatment may play a role in recurrent disease but must be
evaluated on a case-by-case basis.
Baergen et al. (7) 55 Cases Significant factors associated with adverse survival in the present series were age over 35 years (P =0.025),
interval since the last pregnancy of over 2 years (P =0.014), deep myometrial invasion (P =0.006), stage III or IV
(P <0.0005), maximum high HCG level >1000 mIU/ml (P =0.034), extensive coagulative necrosis (P =0.024),
high mitotic rate (P =0.005), and the presence of cells with clear cytoplasm (P <0.0005).
Lan et al. (3) 5 Cases Lymph node metastasis is one way of spread in PSTT. Retroperitoneal node, especially para-aortic node is the
most common site of lymphatic spread. EGFR and VEGF may be commonly expressed in PSTT tumors.
Hassadia et al. (1) 17 Cases Hysterectomy is the primary mode of treatment in the majority of cases. However, chemotherapy can still play a
major role when curative surgery is not feasible
Chang et al. (20) 88 Cases FIGO stage is the most important prognostic factor, and complete removal of all lesions provided good outcomes
in PSTT patients. For those with unresectable tumors, combination chemotherapy showed a high response rate,
but only a few achieved a complete response.
Schmid et al. (8) 62 Cases Stage-adapted management with surgery for stage I disease, and combined surgery and chemotherapy for stage
II, III, and IV disease could improve the effectiveness of treatment for placental-site trophoblastic tumors. Use of
48 months since antecedent pregnancy as a prognostic indicator of survival could help select patients for
risk-adapted treatment.
Hoekstra et al. (28) 7 Cases Advanced FIGO stage, long interval from last known pregnancy to diagnosis, and high mitotic count were
adverse prognostic indicators for survival in PSTT. All patients with PSTT should undergo initial hysterectomy with
other surgical procedures, as indicated. Chemotherapy, usually EMA/EP, should be used in patients with
advanced PSTT and may be considered in patients with FIGO stage I disease with length of time from
antecedent pregnancy>2 years or high mitotic.
Papadopoulos et al. (23) 34 Cases Risk factors for death include lung metastatic involvement (50%) and an antecedent pregnancy interval of 4 years
or more (100%). In contrast, those with no extra pelvic disease or a pregnancy interval of less than 4 years had
100% survival. In two-thirds of patients with disease limited to the uterus, surgery alone was curative.
Shen et al. (32) 6 Cases Fertility-conserving therapy for young women with PSTT would be practicable if the patient is younger than
35 years, strongly desires to preserve fertility and responds well to chemotherapy and conservative surgery, the
pathological results of which do not show poor prognostic factors and the gross pathologic type does not present
markedly enlarged uterus, diffuse infiltrative, and diffuse multifocal disease within the uterus.
Zhao et al. (37) 11 Cases Pathologic diagnosis of PSTT was the gold standard. Multidrug chemotherapy combined with hysterectomy was
effective in metastasis cases.
treatment conservative of fertility can be discussed with patients
who wish to become pregnant again, have high motivation, good
prognosis factors, and a thorough discussion.
A lymph node sampling is generally recommended.
Chemotherapy is usually not recommended at stage I, but can play
a role in cases of poor prognosis. Currently, there is no consensus
on the best chemotherapeutic treatment.
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